恩替卡韦治疗失代偿期乙型肝炎肝硬化3年疗效观察

doi:10.3969/j.issn.1672-5069.2017.05.031

Abstract

Luo Xianping，Jing Jisheng，Chen Hongbo，et al.. Observation on clinical efficacy of entecavir in treatment of patients with decompensated hepatitis B cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(5): 614-615.

References

[1] 严丽波，唐红. 慢性乙型肝炎诊治进展和展望. 实用医院临床杂志，2016，13（2）：5-9.
[2] Luvisa BK，Hassanein TI.Hepatitis B virus infection and liver decompensation.Clin Liver Dis，2016，20（4）:681-692.
[3] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2015年版）. 实用肝脏病杂志，2016，19（3）：Ⅴ-ⅩⅩⅢ.
[4] 盛秋菊，窦晓光. 2015年亚太肝病学会乙型肝炎管理临床实践指南草案解读. 中国内科杂志，2015，35（9）:744-747.
[5] Terrault NA，Bzowej NH，Chang KM，et al．AASLD guidelines fortreatment of chronic hepatitis B．Hepatology，2016，63（1）:261-283.
[6] Lian JS，Zeng LY，Chen JY，et al. De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis. World J Gastroenterol，2013，19（37）:6278-6283.
[7] Wang FY，Li B，Li Y，et al. Entecavir for patients with hepatitis B decompensated cirrhosis in China:a meta-analysis. Sci Rep，2016，6:32722-32730.
[8] Lee SK，Song MJ，Kim SH，et al. Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis. World J Gastroenterol，2017，23（13）:2396-2403.
[9] Myers RP，Shaheen AA，Hubbard JN，et al. Characteristics of patients with cirrhosis who are dischargedfrom the hospital against medical advice. Clin Gastroenterol Hepatol，2009，7:786-792.
[10] Lefton HB，Rosa A，Cohen M. Diagnosis and epidemiology of cirrhosis. Med Clin North Am，2009，93:787-799.
[11] Guan R，Lui HF.Treatment of hepatitis B in decompensated liver cirrhosis. Int J Hepatol，2011，2011:918017-918027.
[12] Fontana RJ. Management of patients with decompensated HBV cirrhosis. Semin Liver Dis，2003，23:89-100.
[13] Fontana RJ，Hann HW，Perrillo RP，et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology，2002，123: 719-727.

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[3]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[4]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[5]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[6]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[7]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[8]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[9]	Zhu Yage, Liu Jinfeng.. Therapeutic efficacy of adenosine methionine and glycyrrhizin combination in treatment of patients with alcoholic cirrhosis and its effect on serum BGP levels [J]. Journal of Practical Hepatology, 2019, 22(6): 872-875.
[10]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[11]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[12]	Liu Li, Yang Lie, Chen Haiyang, et al.. Changes of hemodynamics after splenectomy combined with pericardial devascularization in patients with cirrhotic portal hypertention complicated by splenic artery steal syndrome [J]. Journal of Practical Hepatology, 2019, 22(6): 884-887.
[13]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[14]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[15]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.

Observation on clinical efficacy of entecavir in treatment of patients with decompensated hepatitis B cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments